Brainfog; Headache; Little sore arm; Metallic taste at moment they administered first shot and second shot; This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (Metallic taste at moment they administered first shot and second shot), FEELING ABNORMAL (Brainfog), HEADACHE (Headache) and VACCINATION SITE PAIN (Little sore arm) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031A21A and 020B21A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included CYCLOBENZAPRINE, CEFIXIME (FLEXERIL [CEFIXIME]), GABAPENTIN, LEVOTHYROXINE, MELOXICAM, METFORMIN (Metformin XR) and SPIRONOLACTONE for an unknown indication.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Mar-2021, the patient experienced DYSGEUSIA (Metallic taste at moment they administered first shot and second shot) and VACCINATION SITE PAIN (Little sore arm). On 16-Mar-2021, the patient experienced FEELING ABNORMAL (Brainfog) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency and IBUPROFEN for Adverse event, at an unspecified dose and frequency. On 16-Mar-2021, FEELING ABNORMAL (Brainfog) outcome was unknown, HEADACHE (Headache) and VACCINATION SITE PAIN (Little sore arm) had resolved. At the time of the report, DYSGEUSIA (Metallic taste at moment they administered first shot and second shot) outcome was unknown. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 14-Apr-2021 and was forwarded to Moderna on 14-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of DYSGEUSIA (Metallic taste at moment they administered first shot and second shot), FEELING ABNORMAL (Brainfog), HEADACHE (Headache) and VACCINATION SITE PAIN (Little sore arm) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031A21A and 020B21A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included CYCLOBENZAPRINE, CEFIXIME (FLEXERIL [CEFIXIME]), GABAPENTIN, LEVOTHYROXINE, MELOXICAM, METFORMIN (Metformin XR) and SPIRONOLACTONE for an unknown indication.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Mar-2021, the patient experienced DYSGEUSIA (Metallic taste at moment they administered first shot and second shot) and VACCINATION SITE PAIN (Little sore arm). On 16-Mar-2021, the patient experienced FEELING ABNORMAL (Brainfog) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency and IBUPROFEN for Adverse event, at an unspecified dose and frequency. On 16-Mar-2021, FEELING ABNORMAL (Brainfog) outcome was unknown, HEADACHE (Headache) and VACCINATION SITE PAIN (Little sore arm) had resolved. At the time of the report, DYSGEUSIA (Metallic taste at moment they administered first shot and second shot) outcome was unknown. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.